BlackRock
TELO icon

BlackRock’s Telomir Pharmaceuticals TELO Stock Holding History

BlackRock’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$376K Buy
289,198
+3,744
+1% +$4.78K ﹤0.01% 4599
2025
Q4 		$380K Sell
285,454
-5,979
-2% -$8.63K ﹤0.01% 4555
2025
Q3 		$405K Sell
291,433
-78,643
-21% -$119K ﹤0.01% 4511
2025
Q2 		$463K Sell
370,076
-830,485
-69% -$1.92M ﹤0.01% 4464
2025
Q1 		$3.88M Buy
1,200,561
+143,586
+14% +$628K ﹤0.01% 3744
2024
Q4 		$4.35M Buy
1,056,975
+690,097
+188% +$3.25M ﹤0.01% 3780
2024
Q3 		$2.36M Buy
366,878
+278,979
+317% +$1.36M ﹤0.01% 3950
2024
Q2 		$423K Buy
+87,899
New +$548K ﹤0.01% 4386

Other funds holding TELO

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $833M AUM 11.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
WIA
World Investment Advisors Santa Barbara, California $6.2B AUM 19.68% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

BlackRock's TELO Position: Q1 2026 in Review

BlackRock increased its Telomir Pharmaceuticals (TELO) stake by 1.3% in Q1 2026, buying an estimated $4.78K and bringing the position to 289,198 shares worth $376K. The position accounts for ﹤0.01% of the portfolio, ranked #4599.

BlackRock first reported a position in TELO in Q2 2024 and has held it in 8 quarters since. The position peaked at $4.35M in Q4 2024. 27 funds tracked by Wall St. Rank hold TELO as of Q1 2026.

  • BlackRock held 289,198 shares of Telomir Pharmaceuticals worth $376K as of Q1 2026.
  • BlackRock bought 3,744 Telomir Pharmaceuticals shares in Q1 2026, an estimated $4.78K.
  • Telomir Pharmaceuticals made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4599 holding.
  • BlackRock first reported a position in Telomir Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • BlackRock's Telomir Pharmaceuticals position peaked at $4.35M in Q4 2024.
  • 27 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.